Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.

Cisgender Men
Gay and Bisexual Men Who Have Sex with Men
Transgender Women
Tracking and Translating the Field